Following the announcement on Thursday, shares of Recro Pharma dropped in dramatic fashion by nearly 55 percent to close the trading day at $5.63.
The post Recro Pharma’s Shares Plunges Following FDA Letter appeared first on Investing News Network.
Original Article: Recro Pharma’s Shares Plunges Following FDA Letter